Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acquired Immunodeficiency Syndromes Clear all
Active, not recruiting Not applicable Interventional

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

NCT06316739
View directory record Official record
Conditions
HIV Infections, HCV, Overdose
Interventions
Ganchero intervention
Behavioral
Lead sponsor
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02685020
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development and Preliminary Trial of a Brief, Portable Health Intervention for Rural Sexual Minority Emerging Adults

NCT03751020
View directory record Official record
Conditions
Depression, Suicidality, Substance Abuse, HIV, Minority Stress
Interventions
Expressive Writing (EW) Intervention, Self-Affirmation (SA) Intervention, Control
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 29 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Worcester, Massachusetts • Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

NCT06568042
View directory record Official record
Conditions
Neuropathic Pain, Distal Sensory Polyneuropathy
Interventions
LY3848575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Chandler, Arizona • Phoenix, Arizona • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Not applicable Interventional

A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)

NCT00002275
View directory record Official record
Conditions
HIV Infections
Interventions
Fat Emulsion 2%, Fat Emulsion 20%
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 4 Interventional

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

NCT00677300
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Darunavir, Ritonavir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Not applicable Interventional

Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment

NCT02228044
View directory record Official record
Conditions
Suicide, Alcohol Abuse, Drug Abuse, HIV
Interventions
Prevention program
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
13 Years to 18 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

NCT01869634
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection
Interventions
darunavir with ritonavir and fixed-dose viread+emtricitabine daily
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Jul 24, 2026, 1:09 PM EDT
Completed No phase listed Observational

A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1

NCT00001121
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

NCT05099965
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections, Vaccine
Interventions
CMV-MVA Triplex, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIV Prevention Among Latino MSM: Evaluation of a Locally Developed Intervention

NCT01626898
View directory record Official record
Conditions
Risk Reduction Behavior
Interventions
HOLA en Grupos, General Health intervention (comparison intervention )
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PrEP SMART Phase I Trial

NCT02895893
View directory record Official record
Conditions
At Risk for HIV
Interventions
PrEP Smart
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

NCT03251144
View directory record Official record
Conditions
HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Interventions
Switch to E/C/FTC/TAF daily
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

NCT00000675
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 1:09 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898
View directory record Official record
Conditions
Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Interventions
Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Not applicable Interventional

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

NCT00002216
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir, Nelfinavir mesylate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 1:09 PM EDT
Completed No phase listed Observational

Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection

NCT00001701
View directory record Official record
Conditions
Cryptococcosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Results available

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

NCT00844519
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
Interventions
Maraviroc, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supporting Trans Affirmation, Relationships, and Sex, Phase 3

NCT06001307
View directory record Official record
Conditions
HIV, Violence, Gender-Based, Violence, Domestic, Risk Reduction Behavior
Interventions
Program STARS (Supporting Trans Affirmation, relationships, and Sex), Relaxation and Stress Reduction
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

NCT00001053
View directory record Official record
Conditions
HIV Infections
Interventions
HIV p17/p24:Ty-VLP, Aluminum hydroxide
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1996
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Doravirine, Rifapentine and Isoniazid Interaction

NCT03886701
View directory record Official record
Conditions
Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
Interventions
Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Jul 24, 2026, 1:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Advanced HIV Prevention (PrEP Chicago)

NCT02896699
View directory record Official record
Conditions
HIV
Interventions
PrEP Intervention Group, Control Group
Behavioral · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Jul 24, 2026, 1:09 PM EDT
Completed No phase listed Observational

Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center

NCT00870857
View directory record Official record
Conditions
HIV Infections, Emphysema, Chronic Obstructive Pulmonary Disease, Pneumocystis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 24, 2026, 1:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Tailored Motivational Interviewing Implementation-Effectiveness Trial in Multidisciplinary Adolescent HIV Care Settings

NCT03681912
View directory record Official record
Conditions
HIV Infections, Adolescent Development, Care Eliciting Behavior, Patient Non-Compliance, Patient Refusal of Treatment
Interventions
Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS), Randomized Guided Development of COPs with an internal facilitator after one year of implementation., CoP development without internal facilitation.
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 24, 2026, 1:09 PM EDT